Cargando…

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) still remains intractable disease with few therapeutic options. Programmed death-ligand 1 (PD-L1), which is essential for immune evasion, is involved in the pathogenesis of ESCC and thus is a potential therapeutic target. PIK3CA, KRAS, and BRAF m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hong Kyu, Kwon, Mi Jung, Ra, Yong Joon, Lee, Hee Sung, Kim, Hyoung Soo, Nam, Eun Sook, Cho, Seong Jin, Park, Hye-Rim, Min, Soo Kee, Seo, Jinwon, Choe, Ji-Young, Min, Kyueng-Whan, Kang, So Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557072/ https://www.ncbi.nlm.nih.gov/pubmed/33054840 http://dx.doi.org/10.1186/s13000-020-01045-4

Ejemplares similares

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Patra, Satyajit, et al.
Publicado: (2017)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer
por: Wang, Chengfeng, et al.
Publicado: (2022)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
por: Nam, Soo Kyung, et al.
Publicado: (2016)

Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
por: Kwon, Mi Jung, et al.
Publicado: (2017)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
por: Mao, Chen, et al.
Publicado: (2012)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
por: Choi, Yong Won, et al.
Publicado: (2016)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
por: Reggiani Bonetti, Luca, et al.
Publicado: (2018)

Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA
por: Chang, Li-Chun, et al.
Publicado: (2014)

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
por: Brinzan, Costel Stelian, et al.
Publicado: (2022)

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
por: Kim, Joo Hoon, et al.
Publicado: (2016)

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

The Missing Link between (Un)druggable and Degradable KRAS
por: De Vita, Elena, et al.
Publicado: (2020)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
por: Velho, Sérgia, et al.
Publicado: (2008)

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
por: Lurkin, Irene, et al.
Publicado: (2010)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
por: Brandi, Giovanni, et al.
Publicado: (2012)

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
por: Mao, Chen, et al.
Publicado: (2015)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
por: Lee, Joon-Hyop, et al.
Publicado: (2019)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
por: Zhang, Jing, et al.
Publicado: (2015)

Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients
por: Li, Xiaozhou, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oh3fevncs87sifubs3q6m6eke4